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The crystal structure of the title compound, C 18 H 13 NO 4 , the oxidized form of the drug aminaftone used in venous disease therapy, is characterized by the presence of ribbons of hydrogen-bonded molecules parallel to the [111] crystallographic direction and by stacking interactions between rings [centroid-centroid distance between quinone rings = 3.684 (3) Å and between aminobenzoate rings = 4.157 (3) Å ] along the ribbons. Table 1 Hydrogen-bond geometry (Å , ). 1,4-dihydroxy-3-methyl-naphtalen-2-yl ester, which is the active pharmaceutical ingredient of some commercial drugs used in the therapy of chronic venous and lymphatic stasis (De Anna et al., 1989; Martinez et al., 2005) , have shown that this drug substance rapidly undergoes oxidation in solution at room temperature. The oxidized compound, featuring a quinone ring instead of a hydroquinone moiety, is also a potential impurity of the bulk drug. A structure determination of the oxidized form, I, has been undertaken at 170 K.
Related literature
There are two molecules of I, related by the inversion centre, in the triclinic unit cell. The molecular geometry and 
Experimental
Samples of aminonaftone were kindly provided by SIMS (SIMS srl, Reggello Firenze, Italy). Crystals of I, suitable for X-ray diffraction analysis, were obtained by slow evaporation from methanol solutions of aminaftone.
Refinement
Crystals did not diffract strongly and it was deemed that collecting data at θ higher than 72° would not yield improvement.
Hydrogen atoms were in geometrically generated positions, riding, except for the amino H atoms, which were refined freely.
The constraint U(H) = 1.2U eq (C,N), or 1.5U eq (C) for methyl group H atoms, was applied. Range of bond distances involving 
